Rempart Asset Management Inc. Acquires 3,942 Shares of Stryker Corporation $SYK

Key Points

• Rempart Asset Management Inc. increased its holdings in Stryker Corporation by 7.6% during the second quarter, owning 55,531 shares valued at approximately $21.97 million as of their latest SEC filing.
• Several large investors have recently adjusted their positions in Stryker, contributing to the fact that 77.09% of the stock is currently owned by hedge funds and other institutional investors.
• Stryker Corporation reported a quarterly earnings per share (EPS) of $3.13, surpassing analysts' expectations, and set its FY 2025 guidance at 13.400-13.600 EPS.

Rempart Asset Management Inc. boosted its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 7.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 55,531 shares of the medical technology company's stock after purchasing an additional 3,942 shares during the quarter. Stryker comprises 4.2% of Rempart Asset Management Inc.'s portfolio, making the stock its 12th largest position. Rempart Asset Management Inc.'s holdings in Stryker were worth $21,970,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in SYK. Sunflower Bank N.A. raised its stake in Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company's stock valued at $275,000 after buying an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC raised its position in shares of Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company's stock worth $341,000 after purchasing an additional 27 shares during the last quarter. Continuum Advisory LLC boosted its stake in Stryker by 5.8% in the 1st quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company's stock worth $198,000 after purchasing an additional 29 shares in the last quarter. Oakworth Capital Inc. grew its position in Stryker by 0.5% during the 1st quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company's stock valued at $2,283,000 after purchasing an additional 29 shares during the last quarter. Finally, Strategy Asset Managers LLC increased its stake in Stryker by 1.4% during the 1st quarter. Strategy Asset Managers LLC now owns 2,134 shares of the medical technology company's stock valued at $794,000 after purchasing an additional 29 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SYK. Wells Fargo & Company upped their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Truist Financial set a $415.00 price objective on shares of Stryker and gave the stock a "hold" rating in a report on Monday, August 4th. Evercore ISI upped their price objective on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Rothschild Redb raised Stryker to a "hold" rating in a report on Thursday, September 18th. Finally, BTIG Research restated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Fourteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $430.33.

Stryker Stock Performance

SYK stock opened at $368.83 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a market cap of $141.01 billion, a P/E ratio of 48.85, a price-to-earnings-growth ratio of 2.66 and a beta of 0.93. The stock's fifty day moving average price is $385.71 and its 200-day moving average price is $379.18.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Insider Activity at Stryker

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.20% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.